Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen With Risk Factors:A Single-Arm, Multicenter Clinical Trial

NCT06251947 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT06251947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06251947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen With Risk Factors:A Single-Arm, Multicenter Clinical Trial
Lead sponsor
Shandong University
Phase
Phase 2
Overall status
Recruiting
Start date
April 15, 2024
Completion date
December 31, 2026
Enrollment
83 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, ovarian cancer